1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Trans Genic Inc.

Trans Genic Inc.

2342.T
Trans Genic Inc.JP flagTokyo Stock Exchange
221.00
JPY
+1.00
- -
3.68BMarket Cap

Total Valuation

Trans Genic Inc. carries a market capitalization of 3.68B, placing it among publicly traded companies globally. Its enterprise value stands at 4.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.68B
Enterprise Value4.43B

Share Statistics

Trans Genic Inc. currently has 16.65M shares outstanding.

Shares Outstanding16.65M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Trans Genic Inc. trades at a trailing price-to-earnings ratio of 249.67. The price-to-sales ratio is 0.59, and the price-to-book ratio stands at 2.09.

PE Ratio249.67
PS Ratio0.59
PB Ratio2.09
P/TBV Ratio0.77
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Trans Genic Inc. trades at an EV/EBITDA multiple of 4,856.75 and an EV/FCF ratio of 255.39. The EV/Sales ratio of 0.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4,856.75 provides insight into valuation relative to core operating earnings.

EV / Sales0.66
EV / EBITDA4,856.75
EV / EBIT4,856.75
EV / FCF255.39

Financial Position

Trans Genic Inc. maintains a current ratio of 1.95, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.51, indicating elevated leverage, while an interest coverage ratio of 0.04 demonstrates limited ability to service its debt obligations.

Current Ratio1.95
Quick Ratio0.63
Debt / Equity46.51
Debt / EBITDA2,931.27
Interest Coverage0.04

Financial Efficiency

Return on Equity (ROE)-2.19
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.15

Taxes

Income Tax-12.80M
Effective Tax RateN/A

Stock Price Statistics

Trans Genic Inc.'s stock has gained approximately 30% over the past 52 weeks. The 50-day moving average sits at 236.08, while the 200-day moving average is 257.42.

Beta (5Y)N/A
52-Week Price Change30%
50-Day Moving Average236.08
200-Day Moving Average257.42
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Trans Genic Inc. generated 6.71B in revenue and converted that into -44.38M in net income, yielding earnings per share of -2.30. EBITDA reached 913,000.00, while operating income came in at 913,000.00.

Revenue6.71B
Gross Profit1.08B
Operating Income913,000.00
Pretax Income-51.00M
Net Income-44.38M
EBITDA913,000.00
EBIT913,000.00
Earnings Per Share (EPS)-2.30

Balance Sheet

Trans Genic Inc. holds 2.27B in cash and equivalents against 2.68B in total debt, resulting in a net debt position of 409.91M. Total book value stands at 1.89B, with working capital of 3.39B providing operational flexibility.

Cash & Cash Equivalents2.27B
Total Debt2.68B
Net Debt409.91M
Equity (Book Value)1.89B
Book Value Per Share113.60
Working Capital3.39B

Margins

Trans Genic Inc. operates with a gross margin of 16.17, reflecting its pricing power and cost economics. The operating margin of 0.01 and net profit margin of -0.66 provide insight into operational efficiency.

Gross Margin16.17
Operating Margin0.01
Pretax Margin-0.76
Profit Margin-0.66
EBITDA Margin0.01

Stock Splits

Trans Genic Inc.'s most recent stock split took place on March 27, 2013 with a 1:100 split ratio.

Last Split Date3/27/2013
Split Ratio1:100

Scores

Trans Genic Inc. posts an Altman Z-Score of 1.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.83